In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species.
The in vitro activity of a new pneumocandin, L-743,872, was evaluated with 108 strains of Candida and compared with the activities of various antifungals. L-743,872 demonstrated the best activity against azole-susceptible and -resistant strains of C. albicans, C. glabrata, C. tropicalis, C. parapsilosis, and C. kefyr and less activity against C. krusei, C. lusitaniae, and C. guilliermondii.
Vazquez
J A
JA
Department of Medicine, Wayne State University School of Medicine, and Detroit Veterans Administration Medical Center, Michigan, USA.
Lynch
M
M
Boikov
D
D
Sobel
J D
JD
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000935:Antifungal Agents / Q000494:pharmacology*; D001393:Azoles / Q000494:pharmacology*; D002175:Candida / Q000187:drug effects*; D000077336:Caspofungin; D004351:Drug Resistance; D054714:Echinocandins; D055666:Lipopeptides; D008826:Microbial Sensitivity Tests; D010455:Peptides; D010456:Peptides, Cyclic
D000900:Anti-Bacterial Agents; D000935:Antifungal Agents; D001393:Azoles; D054714:Echinocandins; D055666:Lipopeptides; D010455:Peptides; D010456:Peptides, Cyclic; D000077336:Caspofungin